WO2001057208A3 - Mlp gene, nucleic acids, polypeptides and the utilization thereof - Google Patents

Mlp gene, nucleic acids, polypeptides and the utilization thereof Download PDF

Info

Publication number
WO2001057208A3
WO2001057208A3 PCT/EP2001/001042 EP0101042W WO0157208A3 WO 2001057208 A3 WO2001057208 A3 WO 2001057208A3 EP 0101042 W EP0101042 W EP 0101042W WO 0157208 A3 WO0157208 A3 WO 0157208A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
utilization
nucleic acids
mlp
mlp gene
Prior art date
Application number
PCT/EP2001/001042
Other languages
German (de)
French (fr)
Other versions
WO2001057208A2 (en
Inventor
Ralph Knoell
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Priority to JP2001558022A priority Critical patent/JP2003523743A/en
Priority to EP01905718A priority patent/EP1252310A2/en
Priority to AU2001233727A priority patent/AU2001233727A1/en
Publication of WO2001057208A2 publication Critical patent/WO2001057208A2/en
Publication of WO2001057208A3 publication Critical patent/WO2001057208A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention concerns mutated MLP sequences, whereby mutation occurs in base No. 10 of exon 2 of the translated sequence or in the third position of codon 112 in exon 4 of the translated sequence. The invention also concerns a muscle-specific promoter and the utilizations thereof.
PCT/EP2001/001042 2000-02-03 2001-02-01 Mlp gene, nucleic acids, polypeptides and the utilization thereof WO2001057208A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2001558022A JP2003523743A (en) 2000-02-03 2001-02-01 MLP genes, nucleic acids, polypeptides and uses thereof
EP01905718A EP1252310A2 (en) 2000-02-03 2001-02-01 Mlp gene, nucleic acids, polypeptides and the utilization thereof
AU2001233727A AU2001233727A1 (en) 2000-02-03 2001-02-01 Mlp gene, nucleic acids, polypeptides and the utilization thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10004857A DE10004857A1 (en) 2000-02-03 2000-02-03 MLP gene, nucleic acids, polypeptides and their use
DE10004857.9 2000-02-03

Publications (2)

Publication Number Publication Date
WO2001057208A2 WO2001057208A2 (en) 2001-08-09
WO2001057208A3 true WO2001057208A3 (en) 2002-07-25

Family

ID=7629771

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/001042 WO2001057208A2 (en) 2000-02-03 2001-02-01 Mlp gene, nucleic acids, polypeptides and the utilization thereof

Country Status (5)

Country Link
EP (1) EP1252310A2 (en)
JP (1) JP2003523743A (en)
AU (1) AU2001233727A1 (en)
DE (1) DE10004857A1 (en)
WO (1) WO2001057208A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863898A (en) * 1996-10-29 1999-01-26 Incyte Pharmaceuticals, Inc. Human lim proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863898A (en) * 1996-10-29 1999-01-26 Incyte Pharmaceuticals, Inc. Human lim proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EBI / EMBL [online] 1 February 2000 (2000-02-01), CHEN ET AL: "A novel member of the LIM gene family involved in cardiovascular diseases", XP002193081, retrieved from EBI / EMBL accession no. AF121260 Database accession no. AF121260 *
DATABASE EBI / EMBL [online] 18 May 1999 (1999-05-18), ZHAO ET AL: "Use of BAC end sequences from library RPCI-11 for sequence-ready map building", XP002193082, retrieved from EBI / EMBL accession no. AQ530580 Database accession no. AQ530580 *
DATABASE EBI / EMBL 4 May 1995 (1995-05-04), FUNG ET AL: "Mapping of a human LIM protein (CLP) to human chromosome 11p15.1 by fluorescence in situ hybridization", XP002179675, retrieved from EBI accession no. EMBL:HS203241 Database accession no. U20324 *
DATABASE EBI / EMBL 6 January 1999 (1999-01-06), YASUNAGA ET AL: "Cloning and characterization of the human muscle LIM protein gene", XP002179674, retrieved from EBI accession no. EMBL:U72899 Database accession no. U72899 *
LI ET AL: "Mutation analysis of the human muscle LIM protein in patients of familial dilated cardiomyopathy", AM. J. HUMAN GENETICS, vol. 65, no. 4, October 1999 (1999-10-01), pages A-475, XP001031859 *

Also Published As

Publication number Publication date
EP1252310A2 (en) 2002-10-30
JP2003523743A (en) 2003-08-12
AU2001233727A1 (en) 2001-08-14
DE10004857A1 (en) 2001-08-16
WO2001057208A2 (en) 2001-08-09

Similar Documents

Publication Publication Date Title
WO2001053312A8 (en) Novel nucleic acids and polypeptides
WO2001075067A3 (en) Novel nucleic acids and polypeptides
WO2001057188A3 (en) Novel nucleic acids and polypeptides
WO2001057190A3 (en) Novel nucleic acids and polypeptides
WO2002022660A3 (en) Novel nucleic acids and polypeptides
WO2001066689A3 (en) Novel nucleic acids and polypeptides
WO2002031111A3 (en) Novel nucleic acids and polypeptides
WO2001088088A3 (en) Novel nucleic acids and polypeptides
WO2003054152A3 (en) Novel nucleic acids and polypeptides
WO2003025148A3 (en) Novel nucleic acids and polypeptides
WO2002070539A3 (en) Novel nucleic acids and polypeptides
WO2003023013A3 (en) Novel nucleic acids and polypeptides
WO2002081731A3 (en) Novel nucleic acids and polypeptides
WO2004080148A3 (en) Novel nucleic acids and polypeptides
WO2002018424A3 (en) Nucleic acids and polypeptides
IL158159A0 (en) NEW POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNalpha-21 GENE
WO2001079449A3 (en) Novel nucleic acids and polypeptides
WO2002044340A3 (en) Novel nucleic acids and polypeptides
WO2001057208A3 (en) Mlp gene, nucleic acids, polypeptides and the utilization thereof
WO2002077180A3 (en) Novel nucleic acids and polypeptides
WO2000008145A3 (en) Novel genes in control of hematopoiesis
MXPA01009335A (en) Recombinant haemophilus influenzae.
WO1999065450A3 (en) Immunosuppressive agents that inhibit calcineurin function and uses thereof
WO2001087917A8 (en) Novel nucleic acids and polypeptides
WO2001075093A8 (en) Novel nucleic acids and polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001905718

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 558022

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2001905718

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001905718

Country of ref document: EP